A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing

Abstract The Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus needs a fast recognition of effective drugs to save lives. In the COVID-19 situation, finding targets for drug repurposing can be an effective way to present new fast treatments. We have designed a two-step solution to a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mahnaz Habibi, Golnaz Taheri, Rosa Aghdam
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/040ee459edf44619b0834ddbe2d352b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:040ee459edf44619b0834ddbe2d352b0
record_format	dspace
spelling	oai:doaj.org-article:040ee459edf44619b0834ddbe2d352b02021-12-02T17:39:32ZA SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing10.1038/s41598-021-88427-w2045-2322https://doaj.org/article/040ee459edf44619b0834ddbe2d352b02021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88427-whttps://doaj.org/toc/2045-2322Abstract The Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus needs a fast recognition of effective drugs to save lives. In the COVID-19 situation, finding targets for drug repurposing can be an effective way to present new fast treatments. We have designed a two-step solution to address this approach. In the first step, we identify essential proteins from virus targets or their associated modules in human cells as possible drug target candidates. For this purpose, we apply two different algorithms to detect some candidate sets of proteins with a minimum size that drive a significant disruption in the COVID-19 related biological networks. We evaluate the resulted candidate proteins sets with three groups of drugs namely Covid-Drug, Clinical-Drug, and All-Drug. The obtained candidate proteins sets approve 16 drugs out of 18 in the Covid-Drug, 273 drugs out of 328 in the Clinical-Drug, and a large number of drugs in the All-Drug. In the second step, we study COVID-19 associated proteins sets and recognize proteins that are essential to disease pathology. This analysis is performed using DAVID to show and compare essential proteins that are contributed between the COVID-19 comorbidities. Our results for shared proteins show significant enrichment for cardiovascular-related, hypertension, diabetes type 2, kidney-related and lung-related diseases.Mahnaz HabibiGolnaz TaheriRosa AghdamNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mahnaz Habibi Golnaz Taheri Rosa Aghdam A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing
description	Abstract The Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus needs a fast recognition of effective drugs to save lives. In the COVID-19 situation, finding targets for drug repurposing can be an effective way to present new fast treatments. We have designed a two-step solution to address this approach. In the first step, we identify essential proteins from virus targets or their associated modules in human cells as possible drug target candidates. For this purpose, we apply two different algorithms to detect some candidate sets of proteins with a minimum size that drive a significant disruption in the COVID-19 related biological networks. We evaluate the resulted candidate proteins sets with three groups of drugs namely Covid-Drug, Clinical-Drug, and All-Drug. The obtained candidate proteins sets approve 16 drugs out of 18 in the Covid-Drug, 273 drugs out of 328 in the Clinical-Drug, and a large number of drugs in the All-Drug. In the second step, we study COVID-19 associated proteins sets and recognize proteins that are essential to disease pathology. This analysis is performed using DAVID to show and compare essential proteins that are contributed between the COVID-19 comorbidities. Our results for shared proteins show significant enrichment for cardiovascular-related, hypertension, diabetes type 2, kidney-related and lung-related diseases.
format	article
author	Mahnaz Habibi Golnaz Taheri Rosa Aghdam
author_facet	Mahnaz Habibi Golnaz Taheri Rosa Aghdam
author_sort	Mahnaz Habibi
title	A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing
title_short	A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing
title_full	A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing
title_fullStr	A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing
title_full_unstemmed	A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing
title_sort	sars-cov-2 (covid-19) biological network to find targets for drug repurposing
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/040ee459edf44619b0834ddbe2d352b0
work_keys_str_mv	AT mahnazhabibi asarscov2covid19biologicalnetworktofindtargetsfordrugrepurposing AT golnaztaheri asarscov2covid19biologicalnetworktofindtargetsfordrugrepurposing AT rosaaghdam asarscov2covid19biologicalnetworktofindtargetsfordrugrepurposing AT mahnazhabibi sarscov2covid19biologicalnetworktofindtargetsfordrugrepurposing AT golnaztaheri sarscov2covid19biologicalnetworktofindtargetsfordrugrepurposing AT rosaaghdam sarscov2covid19biologicalnetworktofindtargetsfordrugrepurposing
_version_	1718379805089464320

A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing

Ejemplares similares